Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Pazopanib in Second-line Therapy in Renal Cell Carcinoma

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2014 by Associació per a la Recerca Oncologica, Spain.
Recruitment status was:  Active, not recruiting
Trial Form Support S.L.
Information provided by (Responsible Party):
Associació per a la Recerca Oncologica, Spain Identifier:
First received: April 10, 2012
Last updated: March 11, 2014
Last verified: March 2014
The principal aim of the study is to determine the objective response rate that offers the second-line treatment with pazopanib in patients with carcinoma of advanced renal cells that have progressed or that have not tolerated the first line of treatment with a Tyrosine Kinase Inhibitor. The secondary aims are to determine the overall survival and the treatment safety profile for these patients in second-line treatment with pazopanib. The exploratory aim is to determine the correlation between biomarkers in patient blood and tumor samples, and the clinical results obtained with pazopanib.

Condition Intervention Phase
Metastatic Renal Cell Carcinoma
Drug: Pazopanib
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II, Opened, Not Controlled and Multicentric Clinical Trial of Pazopanib in Monotherapy to Determine Efficiency and Safety in Second-line of Treatment in Patients With Carcinoma of Advanced Renal Cells That Have Progressed or Have Not Tolerated the First Line of Treatment With Tyrosine Kinase Inhibitor

Resource links provided by NLM:

Further study details as provided by Associació per a la Recerca Oncologica, Spain:

Primary Outcome Measures:
  • Objective Response Rate [ Time Frame: 30 months ]

    To asses the Objective Response (Complete Response or Partial Response) which provides second-line treatment with pazopanib in patients with carcinoma of advanced renal cell who have progressed or have not tolerated a first line of treatment with a Tyrosine Kinase Inhibitor.

    The Objective Response Rate will be evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Secondary Outcome Measures:
  • Overall Survival [ Time Frame: 30 months ]
    To assess the overall survival in patients treated with second-line treatment with pazopanib.

  • Treatment Safety Profile [ Time Frame: 30 months ]

    To assess the treatment safety profile in patients treated with second-line treatment with pazopanib.

    Safety was assessed using Common Toxicity Criteria (CTC) of the National Cancer Institute (NCI), version 4.0.

Estimated Enrollment: 27
Study Start Date: April 2012
Estimated Study Completion Date: October 2015
Estimated Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pazopanib
800 mg / day of pazopanib in monotherapy
Drug: Pazopanib
800 mg / day of pazopanib in monotherapy.
Other Name: Pazopanib (GW786034; Votrient®)

Detailed Description:

Patients who progress or do not tolerate a first-line treatment with a Tyrosine Kinase Inhibitor will be included consecutively in the study. All patients will receive the same treatment regimen consisting of 800 mg / day of pazopanib in monotherapy.

All patients will receive treatment until there is evidence of progression, evidence of unacceptable toxicity, not compliance, investigator clinical decision or consent withdrawal by the patient.

After treatment, the patient will enter to the follow-up period. During this period the investigator will collect information from subsequent administered treatments and survival of all patients, regardless of the reason for withdrawal, every 8 weeks until the scheduled end of follow-up period, according to protocol. At 30 days after treatment completion, the first follow up visit will be scheduled to assess the possible occurrence of late toxicity. In those patients who complete treatment prior to objectify progression, information about the progression of the disease will be collected.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Signed Inform Consent
  2. Age ≥ 18
  3. Histologically confirmed diagnosis of clear cell renal carcinoma metastatic or locally recurrent unresectable.
  4. Patients must have received only a first-line treatment with a Tyrosine Kinase Inhibitor. Patients must have progressed during treatment or within three months after stopping treatment with these agents. Patients who discontinued treatment with a Tyrosine Kinase Inhibitor for unacceptable toxicity are also eligible for the study.
  5. Patients must have been previously treated by nephrectomy with removal of the primary tumor, except that there is a contraindication (eg liver I extensive bone metastatic disease or primary tumor smaller than 5 cm).
  6. Patients with ECOG PS 0 or 1.
  7. To be included in the study, the renal tumor should be classified in a group of low or intermediate risk according to the Motzer classification.
  8. Eligibility criteria under RECIST v.1.1
  9. Adequate hematologic function:

    Absolute neutrophil count ≥ 1.5 x 109 / L Platelet count ≥ 100 x 109 / L Hemoglobin ≥ 9 g / dL (5.6 mmol / L). Prothrombin time (PT) or international normalized ratio (INR) ≤ 1.2 X ULN. Activated partial thromboplastin time (APTT) ≤ 1.2 X ULN

  10. Adequate hepatic function:

    total bilirubin ≤ 1.5 X ULN ALT ≤ 2.5 x ULN

  11. Adequate renal function:

    Serum creatinine ≤ or 1.5 mg / dL (133 mol / L). If> 1.5 mg / dL, then the calculated creatinine clearance has to be ≥ 50 mL / min (Appendix 1).

    Urine protein / creatinine ratio <1.

  12. Can be included in the study of both fertile and infertile women.

Exclusion Criteria:

  1. Previous malignancy. May be included in the study patients with a disease-free interval of 5 years at the time of inclusion in the study and patients with non-melanoma skin carcinoma completely resected or carcinoma in situ treated successfully.
  2. Previous treatment with more then one Tyrosine Kinase Inhibitor or more than one previous traditional regime (eg, chemotherapy, immunotherapy or chemo-immunotherapy).
  3. Known history or clinical evidence of nervous system metastases or leptomeningeal carcinomatosis, except that metastases in the central nervous system have been previously treated, are asymptomatic and not requiring treatment with corticosteroids or anticonvulsant medication within six months before the first administration of pazopanib.
  4. Clinically significant gastrointestinal disorders that may increase the risk of bleeding gastrointestinal.
  5. Clinically significant gastrointestinal disorders which may affect the absorption of pazopanib.
  6. Presence of uncontrolled infection.
  7. ECG QT interval longer than 480 milliseconds, according to the Bazett formula.
  8. History of one or more of the following cardiovascular conditions within the last 6 months prior to inclusion:

    Cardiac angioplasty or stent placement Myocardial infarction Unstable angina Surgery or coronary bypass Symptomatic peripheral vascular disease

  9. Congestive heart failure Class III or IV, as defined by the New York Heart Association
  10. Poorly controlled hypertension (defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg).
  11. History of stroke (including transient ischemic attack), pulmonary embolism or deep vein thrombosis not treated within 6 months.
  12. Major surgery or major trauma within 28 days prior to administering the first dose of study and / or presence of any unhealed wound, fracture, or ulcer (not considered major procedures such as venous catheter placement with or without a reservoir).
  13. Evidence of bleeding diathesis or active bleeding.
  14. Endobronchial lesions known and / or lesions infiltrating major pulmonary vessels.
  15. Hemoptysis greater than 2.5 milliliters in the 8 weeks before the first administration of study drug.
  16. Any medical condition, psychiatric or any other nature, unstable or severe, which could interfere with patient safety, with the ability to give informed consent or compliance with study procedures.
  17. Inability or lack of willingness to discontinue the use of banned drugs listed in in the previous 14 days, or the time equivalent to 5 half-lives (whichever is greater) at baseline and during treatment with pazopanib.
  18. Treatment with any of the following antineoplastic therapy: radiation therapy, surgery, tumor embolization, chemotherapy, immunotherapy, biologic therapies, investigational therapies or hormone treatments within 14 days, or the time equivalent to 5 half-lives (whichever is greater), to the administration of the first dose of pazopanib.
  19. Any unresolved toxicity from previous cancer therapies> Grade 1 and / or is getting worse in intensity, except for alopecia.
  20. Patients who are at risk of hypersensitivity to pazopanib.
  21. Pregnant or lactating women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01577784

Hospital Universitario Central de Asturias
Oviedo, Asturias, Spain, 33006
Hospital Universitari Son Espases
Palma de Mallorca, Baleares, Spain, 07010
Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, Spain, 08916
Hospital de Bellvitge
Hospitalet de Llobregat, Barcelona, Spain, 08907
Corporació Sanitaria Parc Taulí
Sabadell, Barcelona, Spain, 08208
Hospital del Mar
Barcelona, Spain, 08003
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain, 08025
Hospital General Universitario Gregorio Marañón
Madrid, Spain, 28009
Hospital 12 de Octubre
Madrid, Spain, 28026
Hospital Clínico San Carlos
Madrid, Spain, 28040
Sponsors and Collaborators
Associació per a la Recerca Oncologica, Spain
Trial Form Support S.L.
Study Chair: Joaquim Bellmunt, MD Hospital del Mar
Principal Investigator: Marta Guix, MD Hospital del Mar
Principal Investigator: Juan Manuel Sepúlveda, MD Hospital 12 de Octubre
Principal Investigator: Enrique Gallardo, MD Corporació Sanitaria Parc Taulí
Principal Investigator: Xavier García del Muro, MD Hospital Universitari de Bellvitge
Principal Investigator: Olatz Etxaniz, MD Germans Trias i Pujol Hospital
Principal Investigator: José Luis González Larriba, MD Hospital Clínico San Carlos
Principal Investigator: Jose Angel Arranz, MD Hospital General Universitario Gregorio Marañón
Principal Investigator: Emilio Esteban, MD Hospital Universitario Central de Asturias
Principal Investigator: Aranzazu González del Alba, MD Hospital Son Espases
Principal Investigator: Pablo Maroto, MD Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
  More Information

Responsible Party: Associació per a la Recerca Oncologica, Spain Identifier: NCT01577784     History of Changes
Other Study ID Numbers: APRO02-2011
Study First Received: April 10, 2012
Last Updated: March 11, 2014

Keywords provided by Associació per a la Recerca Oncologica, Spain:
Advanced renal cell carcinoma
second-line treatment with pazopanib
first line of treatment with a Tyrosine Kinase Inhibitor

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases processed this record on April 28, 2017